JAK Inhibitors and Oxidative Stress Control
نویسندگان
چکیده
منابع مشابه
JAK-STAT pathway and JAK inhibitors: a primer for dermatologists
Background: All cellular events depend upon the DNA synthesis and gene expression involving complex interplay between ligands such as interleukins and interferons, with various cell membrane receptors. These ligand-receptors interactions transmit signals within the cell via numerous signal transduction pathways to affect gene expression. Janus kinase/signal transducer and activator of transcrip...
متن کاملJAK inhibitors in myeloproliferative neoplasms
27 Introduction The Janus kinases (JAKs) are a family of 4 nonreceptor tyrosine kinases that play an essential role in mediating cytokine signalling. JAKs associate with cytokine receptors that lack intrinsic kinase activity to mediate cytokine-induced signal transduction via the activation of the STAT transcription factors and other signalling pathways (Figure 1, page 28).1,2 The 4 family memb...
متن کاملJAK inhibitors and myelofibrosis, Einstein and ruxolitinib.
This year marks a decade since the original descriptions of the JAK2 mutation in myeloproliferative neoplasms. 4 In the intervening years we have witnessed this finding influencing diagnostic processes, prognostic determination and more recently therapeutics. Whilst some perhaps naively anticipated that the benefits of JAK2 as a therapeutic target would parallel those of BCR/ABL inhibitors we h...
متن کاملNetwork pharmacology of JAK inhibitors.
Small-molecule inhibitors of the Janus kinase family (JAKis) are clinically efficacious in multiple autoimmune diseases, albeit with increased risk of certain infections. Their precise mechanism of action is unclear, with JAKs being signaling hubs for several cytokines. We assessed the in vivo impact of pan- and isoform-specific JAKi in mice by immunologic and genomic profiling. Effects were br...
متن کاملJAK inhibitors: beyond spleen and symptoms?
The discovery of the JAK2V617F mutation and constitutive JAK activation in myeloproliferative neoplasms (MPN) has radically changed the landscape of these disorders, not only triggering new diagnostic criteria but, more importantly, offering new therapeutic avenues. In 2012, results with ruxolitinib, a JAK1/JAK2 inhibitor, were reported from two randomized phase III studies comparing ruxolitini...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Immunology
سال: 2019
ISSN: 1664-3224
DOI: 10.3389/fimmu.2019.02814